Innovent Biologics (suzhou) Co., Ltd.

Innovent Biologics Co., Ltd.

Xiaolin Liu

Andy Tsun

Cheng Chen

Hemanta Baruah

Xiaoniu Miao

Junjian Liu

Dechao Michael Yu

Min Zhang

Bingliang Chen

Wei Cao

De-Chao Michael Yu

Junfeng Li

Weifeng Huang

Yinjue Wang

Huajing Hu

Eric Krauland

Nadthakarn Boland

Jonathan P Belk

Xiaoning Shen

The invention relates to a novel antibody and an antibody fragment thereof that specifically bind to ALG-3 and a composition comprising the antibody or the antibody fragment. In addition, the invention relates to a nucleic acid encoding the antibody or the antibody fragment thereof, a host cell comprising the nucleic acid, and related use. Furthermore, the invention relates to therapeutic and diagnostic use of the antibody and the antibody fragment. In particular, the invention relates to combination therapy of the antibodies and the antibody fragments described herein with other therapeutic agents, such as anti-PD-1 or anti-PD-L1 antibodies.

Anti-LAG-3 antibody and use thereof

The present invention relates to an antibody and antibody fragment that specifically binds to OX40 and to a composition comprising said antibody or antibody fragment thereof. In addition, the present invention relates to a nucleic acid encoding the antibody or antibody fragment thereof and a host cell comprising the same, and to a related use thereof. In addition, the present invention relates to the use of the antibody and antibody fragment for treatment and diagnosis.

Anti-OX40 antibody and use thereof

The present invention provides an antibody that specifically binds to proprotein convertase subtilisin/kexin type 9 (PCSK9), an antigen-binding fragment of the antibody, and a composition comprising the antibody or the fragment. Also provided are a nucleic acid that encodes the antibody or the fragment, a host cell containing the nucleic acid, and applications of the antibody and fragment in treatment and diagnosis.

Anti-PCSK9 antibody and use thereof

Disclosed is a nanobody against the human programmed death factor PD-LI. The antibody has the function of blocking the binding of PD-LI to the receptor PD-I. Disclosed are the nanobody and the gene sequence encoding the nanobody, the corresponding expression vector and the host cell capable of expressing the nanobody, and the method for producing the nanobody. At the same time, also disclosed is the sequence of the humanized PD-LI nanobody. The humanized nanobody still has the function of blocking the binding of PD-LI to PD-1, and has a relatively high affinity and a relatively good specificity.

Anti-PD-L1 nanobody and use thereof

Provided herein are pharmaceutical formulations for anti-PD-1 antibodies.

PD-1 antibody formulation

The present invention relates to antibodies that bind human programmed cell death 1 (PD-1), and may be useful for treating cancer alone and in combination with chemotherapy and other cancer therapeutics.

PD-1 antibodies

The present invention provides antibodies that bind human programmed cell death 1 (PD-1), and may be useful for treating cancer alone and in combination with chemotherapy and other cancer therapeutics.

Growing community of inventors

Jiangsu, China

Xiaolin Liu